{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:19:13Z","timestamp":1791357553067,"version":"4.3.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Forest Laboratories, LLC, an Allergan affiliate."}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.jad.2015.06.059","type":"journal-article","created":{"date-parts":[[2015,9,26]],"date-time":"2015-09-26T02:37:02Z","timestamp":1443235022000},"page":"103-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Asenapine: Efficacy and safety of 5 and 10 mg bid in a 3-week, randomized, double-blind, placebo-controlled trial in adults with a manic or mixed episode associated with bipolar I disorder"],"prefix":"10.1016","volume":"190","author":[{"given":"Ronald L.","family":"Landbloom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Mackle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Snow-Adami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maju","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Hundt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2015.06.059_bib1","series-title":"DSM-IV-TR. Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.jad.2015.06.059_bib2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0924-9338(97)86748-X","article-title":"DSM-IH-R psychotic disorders: procedural validity of the mini International neuropsychiatric interview (MINI). Concordance and causes for discordance with the CIDI","volume":"13","author":"Amorim","year":"1998","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.jad.2015.06.059_bib3","series-title":"Handbook of Psychiatric Measures","first-page":"165","article-title":"Adverse effect measures","author":"Barnes","year":"2000"},{"key":"10.1016\/j.jad.2015.06.059_bib4","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2015.06.059_bib5","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/sim.3495","article-title":"A graphical approach to sequentially rejective multiple test procedures","volume":"28","author":"Bretz","year":"2009","journal-title":"Stat. Med."},{"key":"10.1016\/j.jad.2015.06.059_bib6","series-title":"Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology, Revised","first-page":"217","author":"Guy","year":"1976"},{"key":"10.1016\/j.jad.2015.06.059_bib7","series-title":"Abnormal Involuntary Movement Scale (AIMS). ECDEU Assessment Manual for Psychopharmacology, Revised","first-page":"534","author":"Guy","year":"1976"},{"key":"10.1016\/j.jad.2015.06.059_bib8","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/biomet\/75.4.800","article-title":"A sharper Bonferroni procedure for multiple tests of significance","volume":"75","author":"Hochberg","year":"1988","journal-title":"Biometrika"},{"key":"10.1016\/j.jad.2015.06.059_bib9","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Introductory Guide for Standardised MedDRA Queries (SMQs), Version 16.0, MSSO-DI-6226-16.0.\u00a0Available from: \u3008http:\/\/www.meddra.org\/sites\/default\/files\/guidance\/file\/smq_intguide_16_0_english.pdf\u3009 (retrieved 30.09.14)."},{"key":"10.1016\/j.jad.2015.06.059_bib10","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jad.2015.06.059_bib11","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/archpsyc.62.6.617","article-title":"Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2015.06.059_bib12","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1399-5618.2009.00748.x","article-title":"A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states","volume":"11","author":"McIntyre","year":"2009","journal-title":"Bipolar. Disord."},{"key":"10.1016\/j.jad.2015.06.059_bib13","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1399-5618.2009.00749.x","article-title":"Asenapine versus olanzapine in acute mania: a double-blind extension study","volume":"11","author":"McIntyre","year":"2009","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2015.06.059_bib14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jad.2009.12.028","article-title":"Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial","volume":"122","author":"McIntyre","year":"2010","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2015.06.059_bib15","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jad.2010.04.005","article-title":"Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study","volume":"126","author":"McIntyre","year":"2010","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2015.06.059_bib16","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jad.2013.04.025","article-title":"DSM-5 mixed specifier for manic episodes: evaluating the effect of depressive features on severity and treatment outcomes using asenapine clinical trial data","volume":"150","author":"McIntyre","year":"2013","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2015.06.059_bib17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Mietinnen","year":"1985","journal-title":"Stat. Med."},{"key":"10.1016\/j.jad.2015.06.059_bib18","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/0364-7722(79)90058-4","article-title":"Depressive symptoms in acute schizophrenia","volume":"3","author":"Montgomery","year":"1979","journal-title":"Prog. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2015.06.059_bib19","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2015.06.059_bib20","unstructured":"Saphris (asenapine) package insert, 2015. Actavis Inc; Saint Louis, MO."},{"key":"10.1016\/j.jad.2015.06.059_bib21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/0269881107082944","article-title":"Asenapine: a novel psychopharmacologic agent with a unique human receptor signature","volume":"23","author":"Shahid","year":"2009","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2015.06.059_bib22","series-title":"Handbook of Psychiatric Measures","first-page":"163","article-title":"Adverse effect measures","author":"Simpson","year":"2000"},{"key":"10.1016\/j.jad.2015.06.059_bib23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"10.1016\/j.jad.2015.06.059_bib24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0165-1781(97)00123-6","article-title":"Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP","volume":"73","author":"Spearing","year":"1997","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2015.06.059_bib25","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br. J. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032715300288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032715300288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T08:53:12Z","timestamp":1621068792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032715300288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":25,"alternative-id":["S0165032715300288"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2015.06.059","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Asenapine: Efficacy and safety of 5 and 10mg bid in a 3-week, randomized, double-blind, placebo-controlled trial in adults with a manic or mixed episode associated with bipolar I disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2015.06.059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}